Levosimendan

Calcium sensitiser used in the management of acutely decompensated congestive heart failure

Nº Q162541 ★

Common · Knowledge

Levosimendan

Calcium sensitiser used in the management of acutely decompensated congestive heart failure

Last price

—

Floor price

—

7-day median

—

30-day sales

30-day range

—

In circulation

Price history

Show table

Date	median	Low	High	sales

Sales history

Last sale: —
30-day average: —
30-day low: —
30-day high: —
Sales 7d: 0
Sales 30d: 0

No sales yet.

Anonymous sales: no buyer or seller shown. Figures count player-to-player sales only.

From Wikipedia

Levosimendan (INN) is a calcium sensitizer used in the management of acutely decompensated congestive heart failure. It is marketed under the trade name Simdax (Orion Corporation). Overall the drug has a two fold mechanism of action. It leads to greater inotropy by increasing the calcium sensitivity as it binds to troponin and this results in a greater positive inotrophic force. Secondly, the drug is able to open ATP-sensitive potassium channels in vascular smooth muscle cells, and the vascular dilatory effects of the drug lead to a decreased preload and afterload, putting less work on the heart. This drug is in the process of review by the FDA but has not been approved for use in the United States yet.

Text: Wikipédia, CC BY-SA 4.0. · Image: Yikrazuul (Public domain) ·

Related cards

Levomethamphetamine

Chemical compound

Nº Q402846 ★★

Levofloxacin

Chemical compound

Nº Q424193 ★★★

Tolvaptan

Selective, competitive vasopressin receptor 2 antagonist used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone

Nº Q426132 ★★

Pinaverium bromide

Chemical compound

Nº Q1236146 ★

Levosulpiride

Chemical compound

Nº Q1452256 ★★★

Moxonidine

Chemical compound

Nº Q419944 ★★★